Iron Parameters in Deferred Donors

Published: 17-04-2012
Last updated: 30-04-2024

The purpose of this study is to collect blood from accepted and deferred donors so that the necessary measurements can be made in a uniform way and distortion of the results can be prevented or corrected.

Ethical review	Approved WMO
Status	Pending
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON35635

Source
ToetsingOnline

Brief title
IJ-PAD

Condition

- Other condition

Synonym
Iron in donors, population distribution of iron parameters

Health condition

ijzerstatus onder donors

Research involving
Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Sint Radboud
Source(s) of monetary or material Support: Sanquin bloedvoorziening

Intervention

Keyword: blood donors, deferred, iron parameters

Outcome measures

Primary outcome

Celindices in the blood, hemoglobin, ZPP, and thrombocytenindices will be

determined. In a part of the samples, ferritin will also be determined.

Secondary outcome

nvt

Study description

Background summary

Currently four ongoing studies at the the department of Donor Studies are hampered by the lack of information on blood levels of deferred donors. For these studies, information on blood levels in (a random sample of) deferred donors is essential.

Study objective

The purpose of this study is to collect blood from accepted and deferred donors so that the necessary measurements can be made in a uniform way and distortion of the results can be prevented or corrected.

Study design

This is observational, cross sectional, prediction research, with a volume of 2000 test points (1000 deferrals and 1000 subsequent approvals) from Nijmegen and Eindhoven in 2012. After consent , two tubes of blood will be collected from deferred donors . Two tubes of blood will bee removed from the sample bag of the blood donor following the deferral. Celindices in the blood, hemoglobin, ZPP, and thrombocytenindices will be determined. In a part of the samples, ferritin will also be determined.

Study burden and risks

Informed consent will be asked from the deferred donors. The approved donors all have given permission to use their blood for scientific research. They are informed about their possible participation in the study. Accidental finds will be ignored.

Contacts

Public
Universitair Medisch Centrum Sint Radboud

Postbus 9101
6500 HB Nijmegen
NL
Scientific
Universitair Medisch Centrum Sint Radboud

Postbus 9101
6500 HB Nijmegen
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Deferred blood donor
presenting in Nijmegen or Eindhoven

Exclusion criteria

none

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-01-2012
Enrollment:	1000
Type:	Anticipated

Ethics review

Approved WMO

Date:	17-04-2012
Application type:	First submission
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL38277.091.11